Cargando…

Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors

PURPOSE: To evaluate the appearance and size of ablation zones in gadoxetic-acid-enhanced magnetic resonance imaging (MRI) during the first year after irreversible electroporation (IRE) of primary or secondary hepatic malignancies and to investigate potential correlations to clinical features. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales: Bäumler, Wolf, Schicho, Andreas, Schaible, Jan, Verloh, Niklas, Senk, Karin, Wiggermann, Phillip, Stroszczynski, Christian, Beyer, Lukas Phillip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671553/
https://www.ncbi.nlm.nih.gov/pubmed/33201902
http://dx.doi.org/10.1371/journal.pone.0242093
_version_ 1783610951816183808
author Bäumler, Wolf
Schicho, Andreas
Schaible, Jan
Verloh, Niklas
Senk, Karin
Wiggermann, Phillip
Stroszczynski, Christian
Beyer, Lukas Phillip
author_facet Bäumler, Wolf
Schicho, Andreas
Schaible, Jan
Verloh, Niklas
Senk, Karin
Wiggermann, Phillip
Stroszczynski, Christian
Beyer, Lukas Phillip
author_sort Bäumler, Wolf
collection PubMed
description PURPOSE: To evaluate the appearance and size of ablation zones in gadoxetic-acid-enhanced magnetic resonance imaging (MRI) during the first year after irreversible electroporation (IRE) of primary or secondary hepatic malignancies and to investigate potential correlations to clinical features. MATERIAL AND METHODS: The MRI-appearance of the ablation area was assessed 1–3 days, 6 weeks, 3 months, 6 months, 9 months and 1 year after IRE. The size of the ablation zone and signal intensities of each follow-up control were compared. Moreover, relationships between clinical features and the MRI-appearance of the ablation area 1–3 days after IRE were analyzed. RESULTS: The ablation zone size decreased from 5.6 ± 1.4 cm (1–3 days) to 3.7±1.2 cm (1 year). A significant decrease of central hypointensities was observed in T2-blade- (3 months), T2 haste- (6 weeks; 3 months; 6 months; 1 year), T1 arterial phase- (3 months; 1 year), and diffusion-sequences (6 weeks; 3 months; 6 months; 9 months; 1 year). The unenhanced T1-sequences showed significantly increasing central hypointensities (6 weeks; 3 months; 6 months; 9 months; 1 year). Significantly increasing peripheral hypointensities were detected in T1 arterial phase- (3 months; 6 months; 9 months; 1 year) and in T1 portal venous phase-sequences (6 weeks; 3 months; 6 months; 9 months; 1 year). Peripheral hypointensities of unenhanced T1-sequences decreased significantly 1 year after IRE. 1–3 days after IRE central T1 portal venous hypo- or isointensities were detected significantly more often than hyperintensities, if more than 3 IRE electrodes were used. CONCLUSION: Hepatic IRE results in continuous reduction of ablation zone size during the first postinterventional year. In addition to centrally decreasing T1-signal and almost steadily increasing signal in the enhanced T2 haste-, diffusion- and T1 arterial phase-sequences, there is a trend toward long-term decreasing T1 arterial- and portal venous MRI-signal intensity of the peripheral ablation area, probably representing a region of reversible electroporation.
format Online
Article
Text
id pubmed-7671553
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-76715532020-11-19 Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors Bäumler, Wolf Schicho, Andreas Schaible, Jan Verloh, Niklas Senk, Karin Wiggermann, Phillip Stroszczynski, Christian Beyer, Lukas Phillip PLoS One Research Article PURPOSE: To evaluate the appearance and size of ablation zones in gadoxetic-acid-enhanced magnetic resonance imaging (MRI) during the first year after irreversible electroporation (IRE) of primary or secondary hepatic malignancies and to investigate potential correlations to clinical features. MATERIAL AND METHODS: The MRI-appearance of the ablation area was assessed 1–3 days, 6 weeks, 3 months, 6 months, 9 months and 1 year after IRE. The size of the ablation zone and signal intensities of each follow-up control were compared. Moreover, relationships between clinical features and the MRI-appearance of the ablation area 1–3 days after IRE were analyzed. RESULTS: The ablation zone size decreased from 5.6 ± 1.4 cm (1–3 days) to 3.7±1.2 cm (1 year). A significant decrease of central hypointensities was observed in T2-blade- (3 months), T2 haste- (6 weeks; 3 months; 6 months; 1 year), T1 arterial phase- (3 months; 1 year), and diffusion-sequences (6 weeks; 3 months; 6 months; 9 months; 1 year). The unenhanced T1-sequences showed significantly increasing central hypointensities (6 weeks; 3 months; 6 months; 9 months; 1 year). Significantly increasing peripheral hypointensities were detected in T1 arterial phase- (3 months; 6 months; 9 months; 1 year) and in T1 portal venous phase-sequences (6 weeks; 3 months; 6 months; 9 months; 1 year). Peripheral hypointensities of unenhanced T1-sequences decreased significantly 1 year after IRE. 1–3 days after IRE central T1 portal venous hypo- or isointensities were detected significantly more often than hyperintensities, if more than 3 IRE electrodes were used. CONCLUSION: Hepatic IRE results in continuous reduction of ablation zone size during the first postinterventional year. In addition to centrally decreasing T1-signal and almost steadily increasing signal in the enhanced T2 haste-, diffusion- and T1 arterial phase-sequences, there is a trend toward long-term decreasing T1 arterial- and portal venous MRI-signal intensity of the peripheral ablation area, probably representing a region of reversible electroporation. Public Library of Science 2020-11-17 /pmc/articles/PMC7671553/ /pubmed/33201902 http://dx.doi.org/10.1371/journal.pone.0242093 Text en © 2020 Bäumler et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Bäumler, Wolf
Schicho, Andreas
Schaible, Jan
Verloh, Niklas
Senk, Karin
Wiggermann, Phillip
Stroszczynski, Christian
Beyer, Lukas Phillip
Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors
title Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors
title_full Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors
title_fullStr Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors
title_full_unstemmed Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors
title_short Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors
title_sort changes in gadoxetic-acid-enhanced mr imaging during the first year after irreversible electroporation of malignant hepatic tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671553/
https://www.ncbi.nlm.nih.gov/pubmed/33201902
http://dx.doi.org/10.1371/journal.pone.0242093
work_keys_str_mv AT baumlerwolf changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors
AT schichoandreas changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors
AT schaiblejan changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors
AT verlohniklas changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors
AT senkkarin changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors
AT wiggermannphillip changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors
AT stroszczynskichristian changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors
AT beyerlukasphillip changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors